Patents Assigned to Cytos Biotechnology AG
-
Publication number: 20090028886Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus like particle (VLP) and at least one GnRH peptide or fragment or variant thereof linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of GnRH-related diseases and conditions and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: August 4, 2005Publication date: January 29, 2009Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F Bachmann, Alma Fulurija, Gary Jennings, Edwin Meijerink
-
Publication number: 20080292652Abstract: The present invention is in the fields of medicine, immunology, virology and molecular biology. The present invention provides a composition comprising a modified virus-like (VLP) particle derived from RNA bacteriophage AP205. The invention also provides a process for producing the aforementioned VLP. The modified VLP disclosed in the present invention is useful in the production of compositions for inducing immune responses for the prevention or treatment of diseases, disorders including infectious diseases, allergies, cancers and drug addiction. Moreover, the modified VLP disclosed in the present invention is, in particular, useful to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: September 21, 2005Publication date: November 27, 2008Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin F Bachmann, Alain Tissot, Gary Jennings, Regina Renhofa, Paul Pumpens, Indulis Cielens
-
Patent number: 7452541Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: GrantFiled: May 10, 2005Date of Patent: November 18, 2008Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20080274131Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: January 18, 2008Publication date: November 6, 2008Applicants: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7371542Abstract: The present invention relates to nucleic acid molecules and in particular to vectors, comprising at least one gene of interest, at least one scaffold/matrix attached region (S/MAR), at least one origin of replication, and at least one replication initiation factor, cells comprising these, processes for their propagation, and their use, in particular for the high level expression of proteins which can be used as medicaments.Type: GrantFiled: July 12, 2004Date of Patent: May 13, 2008Assignee: Cytos Biotechnology AGInventors: Lidia Ivanova, Philippe Saudan
-
Publication number: 20080095738Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.Type: ApplicationFiled: October 5, 2005Publication date: April 24, 2008Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin Bachmann, Patrik Maurer, Edwin Meijerink, Katrin Schwarz, Karl Proba
-
Publication number: 20080019991Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP and a particular peptide derived from a polypeptide from the TNF-superfamily linked thereto. The invention also provides a process for producing the modified VLP. The modified VLPs of the invention are useful in the production of vaccines for the treatment of autoimmune diseases and bone-related diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: June 2, 2005Publication date: January 24, 2008Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Patrik Maurer, Gunther Spohn
-
Patent number: 7320793Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: January 22, 2008Assignees: Cytos Biotechnology AG, Novartis Pharma AGInventors: Wolfgang A Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Luond, Matthias Staufenbiel, Peter Frey
-
Patent number: 7279165Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: GrantFiled: July 18, 2003Date of Patent: October 9, 2007Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Lūönd, Matthias Staufenbiel, Peter Frey
-
Patent number: 7264810Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: January 18, 2002Date of Patent: September 4, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Publication number: 20070184068Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.Type: ApplicationFiled: December 14, 2006Publication date: August 9, 2007Applicant: Cytos Biotechnology AGInventors: Wolfgang Renner, Martin Bachmann, Indulis Cielens, Conrad Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
-
Patent number: 7229624Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.Type: GrantFiled: December 12, 2003Date of Patent: June 12, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann
-
Publication number: 20070128219Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: November 20, 2006Publication date: June 7, 2007Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20070117129Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a RANKL protein, RANKL fragment or RANKL peptide-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of bone diseases and as a pharmaccine to prevent or cure bone diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.Type: ApplicationFiled: October 30, 2006Publication date: May 24, 2007Applicant: CYTOS BIOTECHNOLOGY AGInventors: Martin Bachmann, Patrik Maurer, Gunther Spohn
-
Publication number: 20070093441Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides a composition comprising a virus-like particle and at least one protein, or peptide of IL-5, IL-13 and/or eotaxin bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of allergic diseases with an eosinophilic component and as a pharmaccine to prevent or cure allergic diseases with an eosinophilic component and to efficiently induce immune responses, in particular antibody responses.Type: ApplicationFiled: August 7, 2006Publication date: April 26, 2007Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Gary Jennings, Ivo Sonderegger
-
Publication number: 20070087331Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides methods using a composition comprising an ordered and repetitive antigen or antigenic determinant array for visualization and selection of B cells specific for the antigen. These B cells are useful for the production of monoclonal antibodies used for therapy, diagnostic or research purposes.Type: ApplicationFiled: May 14, 2004Publication date: April 19, 2007Applicant: Cytos Biotechnology AGInventors: Martin Bachmann, Dominique Gatto
-
Publication number: 20070087409Abstract: The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system.Type: ApplicationFiled: October 2, 2006Publication date: April 19, 2007Applicant: Cytos Biotechnology AGInventor: Martin Bachmann
-
Publication number: 20070065408Abstract: This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct adenovirus infection specifically to cells having said cell surface molecule on their surface. The invention relates to nucleic acid sequences encoding fusion proteins comprising a) a polypeptide derived from the extracellular domain of CD46 and b) a heterologous polypeptide, methods for the production of the modified polypeptides and suitable recombinant expression vectors and host cells. Pharmaceutical compositions comprising the modified polypeptide of the invention are useful together with recombinant, genetically engineered adenovirus of subtype B for the treatment and prophylaxis of disorders and diseases, like cancer.Type: ApplicationFiled: May 27, 2004Publication date: March 22, 2007Applicant: CYTOS BIOTECHNOLOGY AGInventors: Roger Beerli, Martin Bachmann
-
Publication number: 20070048287Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: November 3, 2006Publication date: March 1, 2007Applicant: Cytos Biotechnology AGInventors: Wolfgang Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
-
Patent number: 7138252Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: GrantFiled: July 14, 2003Date of Patent: November 21, 2006Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa